Gossamer Bio, Inc.GOSSEarnings & Financial Report
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
Revenue
$95.8M
Gross Profit
N/A
Operating Profit
$52.1M
Net Profit
$49.2M
Gross Margin
N/A
Operating Margin
54.3%
Net Margin
51.4%
YoY Growth
N/A
EPS
$0.22
Gossamer Bio, Inc. Q2 FY2024 Financial Summary
Gossamer Bio, Inc. reported revenue of $95.8M for Q2 FY2024, with a net profit of $49.2M (up 215.9% YoY) (51.4% margin).
Key Financial Metrics
| Total Revenue | $95.8M |
|---|---|
| Net Profit | $49.2M |
| Gross Margin | N/A |
| Operating Margin | 54.3% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Gossamer Bio, Inc. Q2 FY2024 revenue of $95.8M breaks down across 2 segments, led by License And Service at $88.8M (92.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| License And Service | $88.8M | 92.6% |
| Revenue From Contracts With Collaborators | $7.1M | 7.4% |
Gossamer Bio, Inc. Quarterly Revenue & Net Profit History
Gossamer Bio, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.8M | +47.1% | $-47.2M | -342.3% |
| Q3 FY2025 | $13.3M | +40.2% | $-48.2M | -362.7% |
| Q2 FY2024 | $95.8M | — | $49.2M | 51.4% |
| Q1 FY2024 | $0 | — | $-41.9M | N/A |
| Q3 FY2023 | $0 | — | $-40.0M | N/A |
| Q2 FY2023 | $0 | — | $-42.5M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $95.8M | $13.3M | $13.8M |
| YoY Growth | N/A | N/A | N/A | N/A | 40.2% | 47.1% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Assets | $181.7M | $347.9M | $259.4M | $373.4M | $208.8M | $172.2M |
| Liabilities | $244.5M | $243.3M | $232.6M | $291.9M | $291.2M | $295.0M |
| Equity | $-62.8M | $104.6M | $26.7M | $81.5M | $-82.3M | $-122.8M |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-38.3M | $-34.5M | $-52.3M | $116.3M | $-36.2M | $-48.3M |